Highlighting Fibroblasts Activation in Fibrosis: The State-of-The-Art Fibroblast Activation Protein Inhibitor PET Imaging in Cardiovascular Diseases

Fibrosis is a common healing process that occurs during stress and injury in cardiovascular diseases. The evolution of fibrosis is associated with cardiovascular disease states and causes adverse effects. Fibroblast activation is responsible for the formation and progression of fibrosis. The incipient detection of activated fibroblasts is important for patient management and prognosis. Fibroblast activation protein (FAP), a membrane-bound serine protease, is almost specifically expressed in activated fibroblasts. The development of targeted FAP-inhibitor (FAPI) positron emission tomography (PET) imaging enabled the visualisation of FAP, that is, incipient fibrosis. Recently, research on FAPI PET imaging in cardiovascular diseases increased and is highly sought. Hence, we comprehensively reviewed the application of FAPI PET imaging in cardiovascular diseases based on the state-of-the-art published research. These studies provided some insights into the value of FAPI PET imaging in the early detection of cardiovascular fibrosis, risk stratification, response evaluation, and prediction of the evolution of left ventricular function. Future studies should be conducted with larger populations and multicentre patterns, especially for response evaluation and outcome prediction.

[1]  T. Derlin,et al.  Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors , 2023, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Q. Lin,et al.  Extranodal Rosai-Dorfman disease involving pulmonary artery detected by ^68Ga-FAPI PET/CT and fused ^68Ga-FAPI PET/MRI , 2023, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  M. Uder,et al.  Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04-PET-CT , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  Jun Zhao,et al.  Non-tumoral uptake of 68Ga-FAPI-04 PET: A retrospective study , 2022, Frontiers in Oncology.

[5]  Kuangyu Shi,et al.  [68Ga]Ga-DOTA-FAPI-04 PET/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Xiao Zhang,et al.  Different displays of ^13N-NH_3 myocardial perfusion and cardiac ^68Ga-FAPI PET in immune checkpoint inhibitor–associated myocarditis-induced heart failure , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  S. Dorbala Fibroblast Activation: A Novel Mechanism of Heart Failure in Light Chain Cardiac Amyloidosis? , 2022, JACC. Cardiovascular imaging.

[8]  Xiao Zhang,et al.  ^68Ga-FAPI PET visualize heart failure: from mechanism to clinic , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Y. Zhang,et al.  Myocardial Activity at 18F-FAPI PET/CT and Risk for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. , 2022, Radiology.

[10]  Yan-hui Sheng,et al.  Treatment of myocardial interstitial fibrosis in pathological myocardial hypertrophy , 2022, Frontiers in Pharmacology.

[11]  Gui-xia Pan,et al.  Molecular imaging of fibroblast activity in pressure overload heart failure using [^68 Ga]Ga-FAPI-04 PET/CT , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  D. Mandry,et al.  Detection of acute myocarditis by ECG-triggered PET imaging of somatostatin receptors compared to cardiac magnetic resonance: preliminary results , 2022, Journal of Nuclear Cardiology.

[13]  X. Qin,et al.  Early detection of radiation-induced myocardial damage by [^18F]AlF-NOTA-FAPI-04 PET/CT imaging , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Shuyang Zhang,et al.  Feasibility of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Light-Chain Cardiac Amyloidosis. , 2022, JACC. Cardiovascular imaging.

[15]  Wei Han,et al.  A clinical study on relationship between visualization of cardiac fibroblast activation protein activity by Al18F-NOTA-FAPI-04 positron emission tomography and cardiovascular disease , 2022, Frontiers in Cardiovascular Medicine.

[16]  C. Qin,et al.  Noninvasive Monitoring of Reparative Fibrosis after Myocardial Infarction in Rats Using 68Ga-FAPI-04 PET/CT. , 2022, Molecular pharmaceutics.

[17]  Yuanhua Yang,et al.  Pulmonary artery imaging with 68 Ga-FAPI-04 in patients with chronic thromboembolic pulmonary hypertension , 2022, Journal of Nuclear Cardiology.

[18]  Y. Liu,et al.  Case Report: Multimodal Imaging Guides the Management of an Eosinophilic Leukemia Patient With Eosinophilic Myocarditis and Intracardiac Thrombus , 2022, Frontiers in Cardiovascular Medicine.

[19]  H. Kauczor,et al.  Repetitive Early 68Ga-FAPI PET Acquisition Comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions , 2022, The Journal of Nuclear Medicine.

[20]  J. Björkegren,et al.  Atherosclerosis: Recent developments , 2022, Cell.

[21]  Jian Zhang,et al.  DP1 (Prostaglandin D2 Receptor 1) Activation Protects Against Vascular Remodeling and Vascular Smooth Muscle Cell Transition to Myofibroblasts in Angiotensin II–Induced Hypertension in Mice , 2022, Hypertension.

[22]  Zuoquan Zhao,et al.  ^68Ga-FAPI PET/CT for molecular assessment of fibroblast activation in right heart in pulmonary arterial hypertension: a single-center, pilot study , 2022, Journal of Nuclear Cardiology.

[23]  Jinming Yu,et al.  [18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  K. Imanaka-Yoshida,et al.  The Pathogenesis of Cardiac Fibrosis: A Review of Recent Progress , 2022, International journal of molecular sciences.

[25]  T. Derlin,et al.  Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome , 2022, The Journal of Nuclear Medicine.

[26]  X. Yang,et al.  Increased 68Ga-FAPI Uptake in Active Atherosclerotic Plaque. , 2022, Clinical Nuclear Medicine.

[27]  M. Henein,et al.  Detection of myocardial fibrosis by speckle-tracking echocardiography: from prediction to clinical applications , 2022, Heart Failure Reviews.

[28]  L. Huo,et al.  Increased 68Ga-FAPI Uptake of Symptomatic Intracranial Atherosclerotic Plaque Revealed by PET/MR. , 2022, Clinical nuclear medicine.

[29]  D. Weissman,et al.  CAR T cells produced in vivo to treat cardiac injury , 2022, Science.

[30]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2022, European journal of heart failure.

[31]  Haojun Chen,et al.  68Ga FAPI PET/MRI in Cardiac Amyloidosis. , 2021, Radiology.

[32]  Hubing Wu,et al.  [18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04 , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  Z. Fayad,et al.  Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation , 2021, Scientific Reports.

[34]  S. Nekolla,et al.  Visualization of thermal damage using 68 Ga-FAPI-PET/CT after pulmonary vein isolation , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  J. Czernin,et al.  Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study , 2021, The Journal of Nuclear Medicine.

[36]  Sinem Nihal Esatoglu,et al.  Takayasu arteritis. , 2021, Current opinion in rheumatology.

[37]  Shihua Zhao,et al.  Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  Shuyang Zhang,et al.  Immune checkpoint inhibitor-associated cardiotoxicity detected by 68Ga-DOTATATE PET/CT and 68Ga-FAPI PET/CT. , 2021, European heart journal. Cardiovascular Imaging.

[39]  M. Hacker,et al.  Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls , 2021, The Journal of Nuclear Medicine.

[40]  R. Bonow,et al.  Myocardial Viability Assessment Before Surgical Revascularization in Ischemic Cardiomyopathy: JACC Review Topic of the Week. , 2021, Journal of the American College of Cardiology.

[41]  Xiaotang Yang,et al.  Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review , 2021, Frontiers in Oncology.

[42]  Xue-juan Wang,et al.  68Ga-FAPI PET/MRI in Coronary Heart Disease , 2021, Journal of Nuclear Cardiology.

[43]  Shaobo Yao,et al.  Cerebral Venous Sinus Thrombosis Caused by Neuro-Behçet Disease Accidentally Detected by 68Ga-FAPI PET/CT. , 2021, Clinical nuclear medicine.

[44]  J. Debus,et al.  Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  Jacob C. Ulirsch,et al.  Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants , 2021, Nature Genetics.

[46]  L. Umutlu,et al.  Visualization of Fibroblast Activation After Myocardial Infarction Using 68Ga-FAPI PET , 2021, Clinical nuclear medicine.

[47]  Shaobo Yao,et al.  Diffuse uptake of [68Ga]Ga-FAPI in the left heart in a patient with hypertensive heart disease by PET/CT , 2021, Journal of Nuclear Cardiology.

[48]  Liang Zhao,et al.  68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for the Evaluation of Disease Activity in Takayasu Arteritis. , 2021, Clinical nuclear medicine.

[49]  S. Nekolla,et al.  Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04 , 2021, Journal of Nuclear Cardiology.

[50]  K. Cheng,et al.  Cardiac fibrosis: myofibroblast-mediated pathological regulation and drug delivery strategies. , 2021, Advanced drug delivery reviews.

[51]  U. Haberkorn,et al.  Early Detection of Checkpoint Inhibitor-Associated Myocarditis Using 68Ga-FAPI PET/CT , 2021, Frontiers in Cardiovascular Medicine.

[52]  K. Kerr,et al.  Chronic Thromboembolic Pulmonary Hypertension: JACC Focus Seminar. , 2020, Journal of the American College of Cardiology.

[53]  Nikolaos G. Frangogiannis,et al.  Cardiac fibrosis. , 2020, Cardiovascular research.

[54]  Zuoquan Zhao,et al.  68Ga-FAPI right heart uptake in a patient with idiopathic pulmonary arterial hypertension , 2020, Journal of Nuclear Cardiology.

[55]  Ya-wen Wang,et al.  68Ga-FAPI-04 Accumulation in Myocardial Infarction in a Patient With Neuroendocrine Carcinoma. , 2020, Clinical nuclear medicine.

[56]  S. Nekolla,et al.  Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling , 2020, Journal of Nuclear Cardiology.

[57]  U. Reineke,et al.  571P Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP) , 2020 .

[58]  U. Haberkorn,et al.  Relationship Between Cardiac Fibroblast Activation Protein Activity by Positron Emission Tomography and Cardiovascular Disease , 2020, Circulation. Cardiovascular imaging.

[59]  J. Elrod,et al.  Myofibroblasts and Fibrosis , 2020, Circulation research.

[60]  F. Ruschitzka,et al.  Deletion of fibroblast activation protein provides atheroprotection. , 2020, Cardiovascular research.

[61]  Torsten Kuwert,et al.  Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor , 2020, The Journal of Nuclear Medicine.

[62]  A. Tefferi,et al.  WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic , 2020, American journal of hematology.

[63]  M. Dweck,et al.  Myocardial fibrosis: why image, how to image and clinical implications , 2019, Heart.

[64]  M. Totzeck,et al.  Cardiac fibroblast activation detected by positron emission tomography/computed tomography as a possible sign of cardiotoxicity. , 2019, European heart journal.

[65]  T. Watabe,et al.  Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models , 2019, The Journal of Nuclear Medicine.

[66]  Thomas Lindner,et al.  Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention , 2019, The Journal of Nuclear Medicine.

[67]  E. Jones,et al.  68Ga FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. , 2019, Radiology. Imaging cancer.

[68]  J. Moon,et al.  Myocardial Amyloidosis: The Exemplar Interstitial Disease. , 2019, JACC. Cardiovascular imaging.

[69]  J. Epstein,et al.  Targeting Cardiac Fibrosis with Engineered T cells , 2019, Nature.

[70]  J. Moon,et al.  Multimodality Imaging Markers of Adverse Myocardial Remodeling in Aortic Stenosis. , 2019, JACC. Cardiovascular imaging.

[71]  N. Frangogiannis,et al.  Fibroblasts in the Infarcted, Remodeling, and Failing Heart , 2019, JACC. Basic to translational science.

[72]  H. Roderick,et al.  Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure. , 2019, Journal of the American College of Cardiology.

[73]  Z. Fayad,et al.  68Ga-DOTATATE PET Identifies Residual Myocardial Inflammation and Bone Marrow Activation After Myocardial Infarction , 2019, Journal of the American College of Cardiology.

[74]  H. Kauczor,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[75]  Stephan G. Nekolla,et al.  Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04 , 2019, The Journal of Nuclear Medicine.

[76]  E. Tombetti,et al.  Takayasu arteritis: advanced understanding is leading to new horizons , 2019, Rheumatology.

[77]  Haniye Sadat Sajadi,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[78]  Thomas Lindner,et al.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.

[79]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers , 2018, The Journal of Nuclear Medicine.

[80]  E. V. van Beek,et al.  Progression of Hypertrophy and Myocardial Fibrosis in Aortic Stenosis , 2018, Circulation. Cardiovascular imaging.

[81]  J. Butler,et al.  Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. , 2018, Journal of the American College of Cardiology.

[82]  J. Molkentin,et al.  Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart , 2018, The Journal of clinical investigation.

[83]  E. Puré,et al.  Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts. , 2017, Matrix biology : journal of the International Society for Matrix Biology.

[84]  M. Lindsey,et al.  Cardiac Fibroblast Activation Post-Myocardial Infarction: Current Knowledge Gaps. , 2017, Trends in pharmacological sciences.

[85]  T. Münzel,et al.  From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension , 2017, Thrombosis and Haemostasis.

[86]  S. Lensing,et al.  Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis. , 2016, JACC. Cardiovascular imaging.

[87]  Malina J. Ivey,et al.  Defining the Cardiac Fibroblast. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[88]  S. Prabhu,et al.  The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. , 2016, Circulation research.

[89]  K. Yutzey,et al.  Cardiac Fibrosis: The Fibroblast Awakens. , 2016, Circulation research.

[90]  D. Sutherlin,et al.  Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21* , 2016, The Journal of Biological Chemistry.

[91]  H. Kaufman,et al.  Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis , 2015, Nature Reviews Drug Discovery.

[92]  P. Galuppo,et al.  Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. , 2015, Journal of molecular and cellular cardiology.

[93]  H. Sillesen,et al.  64Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[94]  E. McNally,et al.  The genetic landscape of cardiomyopathy and its role in heart failure. , 2015, Cell metabolism.

[95]  Z. Rancic,et al.  Evaluation of the Radiolabeled Boronic Acid-Based FAP Inhibitor MIP-1232 for Atherosclerotic Plaque Imaging , 2015, Molecules.

[96]  O. Schilling,et al.  Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy , 2014, Proteomics. Clinical applications.

[97]  S. Conway,et al.  Origin, development, and differentiation of cardiac fibroblasts. , 2014, Journal of molecular and cellular cardiology.

[98]  A. Lambeir,et al.  Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). , 2014, Journal of medicinal chemistry.

[99]  N. Frangogiannis,et al.  The pathogenesis of cardiac fibrosis , 2013, Cellular and Molecular Life Sciences.

[100]  W. Fang,et al.  Comparison of 99mTc-MIBI SPECT/18F-FDG PET Imaging and Cardiac Magnetic Resonance Imaging in Patients With Idiopathic Dilated Cardiomyopathy: Assessment of Cardiac Function and Myocardial Injury , 2012, Clinical nuclear medicine.

[101]  M. Ackerman,et al.  Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. , 2011, Journal of the American College of Cardiology.

[102]  Pierre Croisille,et al.  Assessment of myocardial fibrosis with cardiovascular magnetic resonance. , 2011, Journal of the American College of Cardiology.

[103]  S. Hoerstrup,et al.  Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata , 2011, European heart journal.

[104]  E. Domenichini,et al.  Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[105]  Stephanie L. K. Bowers,et al.  The extracellular matrix: at the center of it all. , 2010, Journal of molecular and cellular cardiology.

[106]  M. Reiser,et al.  In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using 68Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors , 2010, Journal of Nuclear Medicine.

[107]  Giulio Gabbiani,et al.  The myofibroblast: one function, multiple origins. , 2007, The American journal of pathology.

[108]  P. McKee,et al.  Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. , 2007, Archives of biochemistry and biophysics.

[109]  A. Ignaszewski,et al.  Eosinophilic myocarditis: case series and review of literature. , 2006, The Canadian journal of cardiology.

[110]  N. Frangogiannis Chemokines in the ischemic myocardium: from inflammation to fibrosis , 2004, Inflammation Research.

[111]  P. McKee,et al.  A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. , 2004, Blood.

[112]  S. Larson,et al.  A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[113]  C. Abbott,et al.  Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis , 1999, Hepatology.

[114]  G. Mengod,et al.  Somatostatin receptor subtypes sst1, sst2, sst3 and sst5expression in human pituitary, gastroentero‐pancreatic and mammary tumors , 1997 .

[115]  A. Scott,et al.  Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  S S Gambhir,et al.  Quantification of Regional Myocardial Blood Flow Using 13N‐Ammonia and Reoriented Dynamic Positron Emission Tomographic Imaging , 1992, Circulation.

[117]  D E Kuhl,et al.  Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. , 1990, Journal of the American College of Cardiology.

[118]  D. Kuhl,et al.  N‐13 Ammonia as an Indicator of Myocardial Blood Flow , 1981, Circulation.

[119]  P. Ogbogu,et al.  Hypereosinophilic Syndrome , 2015, Clinical reviews in allergy and immunology.

[120]  H. Sillesen,et al.  Cu-DOTATATE PET / MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques Studies in Patients Undergoing Endarterectomy , 2015 .

[121]  W. Roberts,et al.  Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. , 2000, Journal of the American College of Cardiology.